Pneumococcal (black bars) and influenza (white bars) vaccine coverage in patients living with comorbidities (A), and immunosuppressive conditions (B) according to age of 65 years,... حسب Benjamin Wyplosz (22032756)

Flowchart of depth estimation based on Warping transform. حسب Du Siqi (20721422)

الموضوعات:

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. حسب Francesca Catto (21253435)

EGF is decreased in individual donor milk, but not pooled donor milk. حسب Christian Tamar (21100605)

Data Sheet 1_Lack of association between genetic variations in CYP3A5 and blood pressure or hypertension risk in the UK biobank.pdf حسب Pia Leibold (21390134)

"…While some previous studies reported that CYP3A5 variants were associated with decreased blood pressure and risk of HTN, others reported no associations. …"

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. حسب Hongliang Chen (538815)

Baseline characteristics. حسب Si-Jing Chen (15350263)

الموضوعات:

Secondary outcome results. حسب Si-Jing Chen (15350263)

الموضوعات:

NSC population and proliferation decrease drastically during the second postnatal week of DG development. حسب Cristina Medina-Menéndez (21800157)

Study selection criteria. حسب Filip Stanicic (17808254)

"…</p><p>FDA-approved and off-label medications used for PTSD treatment did not yield a consistently greater CAPS decrease vs. control arms across trials. …"

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

"…</p><p>FDA-approved and off-label medications used for PTSD treatment did not yield a consistently greater CAPS decrease vs. control arms across trials. …"

PRISMA flow chart. حسب Filip Stanicic (17808254)

"…</p><p>FDA-approved and off-label medications used for PTSD treatment did not yield a consistently greater CAPS decrease vs. control arms across trials. …"

Participants with virologic suppression or failure at week 24. حسب Tosi M. Mwakyandile (16408705)

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. حسب Tosi M. Mwakyandile (16408705)

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. حسب Tosi M. Mwakyandile (16408705)

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. حسب Tosi M. Mwakyandile (16408705)

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. حسب Tosi M. Mwakyandile (16408705)

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. حسب Tosi M. Mwakyandile (16408705)